Join the 'Mepolizumab' group to help and get support from people like you.
Posted 7 Sep 2016 by Drugs.com
WEDNESDAY, Sept. 7, 2016 – A new injectable drug reduces flare-ups in patients with severe asthma that is not controlled by steroid inhalers alone, two new trials show. The drug, benralizumab, is a biologic that works by killing white blood cells called eosinophils. These are present in large numbers in such patients, and they have been linked to severe asthma. If approved by the U.S. Food and Drug Administration, benralizumab would join two similar drugs – mepolizumab (Nucala) and reslizumab (Cinqair) – in fighting hard-to-control asthma, the researchers said. "We can offer patients who frequently require courses of oral corticosteroids and have a certain level of eosinophils [an allergy-related cell easily measured in the blood] a very effective treatment," said study author Dr. J. Mark FitzGerald. He is a professor of respiratory health at the University of British Columbia in ... Read more
Posted 4 Nov 2015 by Drugs.com
November 4, 2015 - The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Asthma is a chronic disease that causes inflammation in the airways of the lungs. During an asthma attack, airways become narrow making it hard to breathe. Severe asthma attacks can lead to asthma-related hospitalizations because these attacks can be serious and even life-threatening. According to the Centers for Disease Control and Prevention, as of 2013, more than 22 million people in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations each year. “This approval offers patients with severe asthma an additional ... Read more